- Home
- EXEL
EXEL
Exelixis Inc.
as 06-20-2025 4:00pm EST
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | 1147 | City: | ALAMEDA |
| Market Cap: | 11.3B | IPO Year: | 2000 |
| Target Price: | $39.59 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.20 | EPS Growth: | 237.58 |
| 52 Week Low/High: | $21.36 - $48.85 | Next Earning Date: | 08-05-2025 |
| Revenue: | $2,298,922,000 | Revenue Growth: | 24.49% |
| Revenue Growth (this year): | 9.37% | Revenue Growth (next year): | 11.05% |
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | EXEL | Director | Jun 3 '25 | Sell | $43.09 | 7,535 | $324,683.15 | 358,882 | |
| Eckhardt Sue Gail | EXEL | Director | Jun 2 '25 | Sell | $43.21 | 18,838 | $805,139.84 | 21,384 | |
| Heyman Tomas J. | EXEL | Director | May 21 '25 | Sell | $44.29 | 4,544 | $201,253.76 | 32,470 | |
| Haley Patrick J. | EXEL | EVP, Commercial | May 20 '25 | Sell | $44.06 | 34,387 | $1,515,091.22 | 412,072 | |
| POSTE GEORGE | EXEL | Director | May 16 '25 | Sell | $45.99 | 20,634 | $948,957.66 | 169,020 | |
| Peterson Amy C. | EXEL | EVP Prod Dev & Med Aff & CMO | May 15 '25 | Sell | $45.47 | 72,776 | $3,309,124.72 | 465,393 | |
| PAPADOPOULOS STELIOS | EXEL | Director | May 15 '25 | Sell | $44.35 | 36,508 | $1,619,129.80 | 1,279,416 | |
| Senner Christopher J. | EXEL | EVP and CFO | May 15 '25 | Sell | $46.00 | 100,000 | $4,600,000.00 | 967,842 | |
| Haley Patrick J. | EXEL | EVP, Commercial | May 14 '25 | Sell | $45.89 | 136,383 | $6,488,503.15 | 412,072 | |
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | May 1 '25 | Sell | $39.00 | 1,508 | $58,812.00 | 693,181 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Exelixis Says Partner Ipsen Gets EU Panel Backing for Cabometyx to Treat Neuroendocrine Tumors
Business Wire
a day ago
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Zacks
2 days ago
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
Zacks
2 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Simply Wall St.
2 days ago
Those who invested in Exelixis (NASDAQ:EXEL) three years ago are up 102%
Zacks
3 days ago
Here's Why Exelixis (EXEL) is a Strong Value Stock
Zacks
4 days ago
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Zacks
8 days ago
Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.